Physician profile
James A Ferrel
NPI 1063457810
$451.29
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $74.01 · 2021: $45.88 · 2022: $30.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $141.26 | 2019-2020 | |
| Amarin Pharma, INC. | $69.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.29 | 2019-2021 | |
| Sanofi Pasteur INC. | $35.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.51 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.05 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $29.43 | 2019-2020 | |
| Shire North American Group INC | $16.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.77 | 2019 | |
| Amgen INC. | $14.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ferrel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.